Literature DB >> 10541249

Fatal secondary increase in serum S-100B protein after severe head injury. Report of three cases.

A Raabe1, V Seifert.   

Abstract

The S-100B protein is a small cytosolic protein that is found in astroglial or Schwann cells. It is highly specific for brain tissue and is increasingly being investigated as a diagnostic tool to assess the neurological damage after head injury, stroke, subarachnoid hemorrhage, and cardiopulmonary bypass. The authors report on three patients with severe head injury with otherwise normal cerebral perfusion pressure, SaO2, PaCO2, and controlled intracranial pressure (ICP), in whom a secondary excessive increase in serum S-100B was observed. In all cases, the S-100B increase was followed by an increase in ICP. All three patients died within 72 hours after the excessive increase in S-100B. These findings indicate that major secondary brain damage may occur at a cellular level without being identified by current neuromonitoring techniques.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10541249     DOI: 10.3171/jns.1999.91.5.0875

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  13 in total

Review 1.  [Neuromonitoring with S-100 protein in the intensive care unit].

Authors:  M Fries; J Bickenbach; S Beckers; D Henzler; R Rossaint; R Kuhlen
Journal:  Anaesthesist       Date:  2004-10       Impact factor: 1.041

Review 2.  Blood-based diagnostics of traumatic brain injuries.

Authors:  Stefania Mondello; Uwe Muller; Andreas Jeromin; Jackson Streeter; Ronald L Hayes; Kevin K W Wang
Journal:  Expert Rev Mol Diagn       Date:  2011-01       Impact factor: 5.225

3.  S100B protein may detect brain death development after severe traumatic brain injury.

Authors:  Juan J Egea-Guerrero; Francisco Murillo-Cabezas; Elena Gordillo-Escobar; Ana Rodríguez-Rodríguez; Judy Enamorado-Enamorado; Jaume Revuelto-Rey; María Pacheco-Sánchez; Antonio León-Justel; Jose M Domínguez-Roldán; Angel Vilches-Arenas
Journal:  J Neurotrauma       Date:  2013-08-28       Impact factor: 5.269

4.  Serum S-100B protein monitoring in patients with severe traumatic brain injury.

Authors:  Stefanos Korfias; George Stranjalis; Efstathios Boviatsis; Christina Psachoulia; Gerard Jullien; Barbara Gregson; A David Mendelow; Damianos E Sakas
Journal:  Intensive Care Med       Date:  2006-12-02       Impact factor: 17.440

5.  B7 homolog 3 aggravates brain injury in a murine model of Streptococcus pneumoniae-induced meningitis.

Authors:  Xuqin Chen; Yanping Wang; Zhedong Wang; Ruhong Yan; Jie Liu; Xiangying Meng; Yan Li; Jianghuai Wang; Jian Wang
Journal:  Exp Ther Med       Date:  2015-03-05       Impact factor: 2.447

6.  Trajectory analysis of serum biomarker concentrations facilitates outcome prediction after pediatric traumatic and hypoxemic brain injury.

Authors:  Rachel Pardes Berger; Michael C Bazaco; Amy K Wagner; Patrick M Kochanek; Anthony Fabio
Journal:  Dev Neurosci       Date:  2010-09-18       Impact factor: 2.984

7.  αII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients.

Authors:  Stefania Mondello; Steven A Robicsek; Andrea Gabrielli; Gretchen M Brophy; Linda Papa; Joseph Tepas; Claudia Robertson; Andras Buki; Dancia Scharf; Mo Jixiang; Linnet Akinyi; Uwe Muller; Kevin K W Wang; Ronald L Hayes
Journal:  J Neurotrauma       Date:  2010-07       Impact factor: 5.269

Review 8.  Clinical applications of biomarkers in pediatric traumatic brain injury.

Authors:  Simon J I Sandler; Anthony A Figaji; P David Adelson
Journal:  Childs Nerv Syst       Date:  2009-11-10       Impact factor: 1.475

9.  Secondary peaks of S100B in serum relate to subsequent radiological pathology in traumatic brain injury.

Authors:  Eric P Thelin; David W Nelson; Bo-Michael Bellander
Journal:  Neurocrit Care       Date:  2014-04       Impact factor: 3.210

Review 10.  Reliability of S100B in predicting severity of central nervous system injury.

Authors:  Stephen M Bloomfield; James McKinney; Les Smith; Jonathan Brisman
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.